L1CA34 Aperçu des actions Labcorp Holdings Inc. fournit des services de laboratoire. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Labcorp Holdings Inc. Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Labcorp Holdings Historique des cours de bourse Prix actuel de l'action US$309.80 Plus haut sur 52 semaines US$339.32 Plus bas sur 52 semaines US$250.00 Bêta 1.04 Variation sur 1 mois 0% Variation sur 3 mois 1.84% Variation sur 1 an 13.49% Variation sur 3 ans -28.02% Variation sur 5 ans n/a Évolution depuis l'introduction en bourse 65.31%
Nouvelles et mises à jour récentes
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians Dec 18
Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health. Dec 13 Labcorp Holdings Inc. Announces Chief Financial Officer Changes
Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024 Oct 24 Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test
Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 25 Voir plus de mises à jour
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians Dec 18
Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health. Dec 13 Labcorp Holdings Inc. Announces Chief Financial Officer Changes
Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024 Oct 24 Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test
Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 25
Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million. Sep 19
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million. Sep 17
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q). Aug 07
Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx Aug 02
Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024 Aug 01
Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024 Jul 25
Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 02
Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials Jun 18
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio Jun 05
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy May 16
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B Apr 30
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. Apr 26
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw Apr 15 Labcorp Declares Quarterly Dividend, Payable on June 12, 2024
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs Apr 10 Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research Apr 02
Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024 Mar 29
Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024 Mar 28
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials Mar 20
Labcorp Launches Weight Loss Management Testing Solutions Mar 07
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024 Feb 16
Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia Jan 31
Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024 Jan 17
Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024 Jan 12
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company. Nov 21
Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test Nov 15
Labcorp Declares a Cash Dividend, Payable on December 12, 2023 Oct 13
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc. Oct 06
Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc. Aug 04
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023 Jul 28 Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million. Jul 25
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health. Jul 14
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company. Jul 12
Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023 Jun 30
Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board Jun 08
Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus Jun 01
Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon. May 17 Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer
Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023 Feb 17
Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023 Jan 19
Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023 Jan 13
Labcorp Announces Executive Changes Jan 06
Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors Oct 14
Labcorp Declares Quarterly Dividend, Payable on December 9, 2022 Oct 13
Laboratory Corporation of America Holdings (NYSE:LH) acquired Certain Outreach Laboratory Assets from Certain Outreach Laboratory Assets. Oct 04
Laboratory Corporation of America Holdings to Report Q3, 2022 Results on Oct 27, 2022 Sep 28
Laboratory Corporation of America Holdings (NYSE:LH) acquired Clinical Outreach Laboratory Business and Select Related Assets of RWJBarnabas Health. Aug 24
Laboratory Corporation of America Holdings Launches Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test Jul 20 Laboratory Corporation of America Holdings to Report Q2, 2022 Results on Jul 28, 2022
Labcorp to Begin Testing for Monkeypox Using the U.S. Centers for Disease Control and Prevention’s Othopoxvirus Test Jul 07 Labcorp Launches New Test for People with Skin Cancer Laboratory Corporation of America Holdings (NYSE:LH) acquired Select Assets from the Clinical Outreach Business of AtlantiCare. May 10
Labcorp Launches Convenient Home Diagnostic Test Collection Service in Collaboration With Getlabs Apr 23
Labcorp Initiates Quarterly Dividend, Payable on June 9, 2022 Apr 08
Laboratory Corporation of America Holdings, Annual General Meeting, May 11, 2022 Apr 01
Laboratory Corporation of America Holdings to Report Q1, 2022 Results on Apr 28, 2022 Mar 29
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Personal Genome Diagnostics Inc. Feb 22
Laboratory Corporation of America Holdings Provides Earning Guidance of 2022 Feb 13
Labcorp Launches Labcorp OnDemand Digital Health Platform Feb 05
Laboratory Corporation of America Holdings (NYSE:LH) entered into a definitive agreement to acquire Personal Genome Diagnostics Inc for $580 million. Dec 24
Laboratory Corporation of America Holdings (NYSE:LH) announces an Equity Buyback for $2,500 million worth of its shares. Dec 10
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Toxikon Corp. Dec 05
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN). Sep 14
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Ovia Health Inc. Aug 14
Labcorp Launches Companion Diagnostic for Amgen’s Newly-Approved Lung Cancer Therapy Jul 03
Laboratory Corporation of America Holdings(NYSE:LH) dropped from Russell 1000 Growth Index Jun 28
Laboratory Corporation of America Holdings(NYSE:LH) dropped from Russell 1000 Dynamic Index Jun 27
Labcorp And OmniSeq Launch INSIGHT, Next-Generation Sequencing Platform to Advance Precision Oncology Jun 15
Labcorp Announces That Pixel by Labcorp COVID-19 PCR Test Home Collection Kits Jun 09
Labcorp to Introduce Combined Oncology Offering At 2021 ASCO® Annual Meeting Jun 03
Labcorp Study Suggests COVID-19 Antibodies Remain At Least 10 Months After Infection May 25
Pixel by Labcorp COVID-19 PCR Test Home Collection Kit Receives FDA Emergency Authorization for Ages 2-17 May 14
Labcorp Revises Earnings Guidance for the Full Year 2021 Apr 30
WELL Health's Circle Medical to Offer Labcorp's At Home COVID-19 Self-Collection Test and Announces Clinical Expansion to Austin and San Diego Markets Mar 11
Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio Feb 24
Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection Feb 18
Labcorp Announces Management Appointments Feb 10
Laboratory Corporation of America Holdings(NYSE:LH) dropped from Russell 1000 Defensive Index Jan 28
Laboratory Corporation of America Holdings Announces Executive Changes Jan 20 Laboratory Corporation of America Holdings to Report Q4, 2020 Results on Feb 11, 2021
LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail Dec 11 Rendement pour les actionnaires L1CA34 BR Healthcare BR Marché 7D 0% 1.6% -0.8% 1Y 13.5% -31.9% -13.7%
Voir le rapport complet des actionnaires
Rendement vs Industrie: L1CA34 a dépassé le secteur BR Healthcare qui a rapporté -31.9 % au cours de l'année écoulée.
Rendement vs marché: L1CA34 a dépassé le marché BR qui a rapporté -13.7 % au cours de l'année écoulée.
Volatilité des prix Is L1CA34's price volatile compared to industry and market? L1CA34 volatility L1CA34 Average Weekly Movement n/a Healthcare Industry Average Movement 6.9% Market Average Movement 5.0% 10% most volatile stocks in BR Market 9.6% 10% least volatile stocks in BR Market 2.9%
Cours de l'action stable: Le cours de l'action de L1CA34 a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de L1CA34 au cours de l'année écoulée.
À propos de l'entreprise Labcorp Holdings Inc. fournit des services de laboratoire. Elle opère à travers deux segments, Diagnostics Laboratories et Biopharma Laboratory Services. La société propose divers tests, tels que des analyses chimiques du sang, des analyses d'urine, des numérations globulaires, des tests thyroïdiens, des tests PAP, des tests d'hémoglobine A1C et de vitamine D, des tests d'antigènes spécifiques de la prostate, des tests de maladies sexuellement transmissibles, des tests d'hépatite C, des cultures et des procédures microbiologiques, ainsi que des tests de dépistage de l'alcoolisme et d'autres toxicomanies.
Afficher plus Labcorp Holdings Inc. Résumé des fondamentaux Comment les bénéfices et les revenus de Labcorp Holdings se comparent-ils à sa capitalisation boursière ? L1CA34 statistiques fondamentales Capitalisation boursière R$116.35b Bénéfices(TTM) R$2.65b Recettes(TTM ) R$77.35b
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) L1CA34 compte de résultat (TTM ) Recettes US$12.71b Coût des recettes US$9.16b Marge brute US$3.55b Autres dépenses US$3.11b Les revenus US$435.50m
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) 5.21 Marge brute 27.92% Marge bénéficiaire nette 3.43% Ratio dettes/capitaux propres 83.2%
Quelles ont été les performances à long terme de L1CA34?
Voir les performances historiques et les comparaisons Dividendes
1.3% Rendement actuel des dividendes
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2024/12/21 21:45 Cours de l'action en fin de journée 2024/09/23 00:00 Les revenus 2024/09/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Labcorp Holdings Inc. est couverte par 48 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Jasper Hellweg Argus Research Company Brian Kemp Dolliver Avondale Partners Eric Coldwell Baird
Afficher 45 plus d'analystes 
